Oral drug near approval results in 58% reduction in relapses

[ActiveMSers]

No one that I know really enjoys taking shots. Okay, that's an understatement. Which is why the results of a Phase III study of cladribine tablets that show a 58% reduction is relapses--double the effectiveness of traditional CRABs and with less risky side effects than Tysabri--is so significant. Merck, the company that developed the drug (they also make Rebif), will start seeking FDA approval later in 2009. Click here to open the pdf press release.

http://news.merck.de/N/0/4BBBA74A36B36D98C1257546005551A8/$File/Clad-e.pdf